The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage…
Browsing: ribociclib
In a recent interview, Peter Fasching, MD, Professor of Women’s Cancer Specialist at the University Hospital in Erlangen, Germany, discussed…
Dr. Sayeh Lavasani, MD, MSc, FRCPC, an Associate Clinical Professor in the Division of Hematology Oncology at the Department of…
KEY TAKEAWAYS: Ribociclib, a CDK4/6 inhibitor, is a promising drug in the treatment of early-stage and metastatic breast cancer, particularly…
Adam Brufsky, MD, PhD from the University of Pittsburgh discussed the higher risk of recurrence in certain breast cancer patients…
iFrame is not supported! Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT…
Ribociclib: SABCS 2022 Phase II RIGHT Choice Trial in Breast Cancer What is the RIGHT Choice ribociclib clinical trial…